MILV Stocks Rally
In the recent past sub penny stocks have dominated the most active names group, but Mistral Ventures (MILV:PK) is looking to buck that trend. MILV is a penny stock that has been dead for some time since the shares traded at .69 cents back in 2010.
However, volume has recently picked up, and a decent short term chart seems to building. Can you take a two or three week spike in MILV activity as gospel ? No way, penny stock charts are very different from established large cap charts, but you have to respect the increased activity in MILV.
Shares of MILV traded up on 10/27/11 on volume of over 257 million shares on a PR that said that the company had reached an agreement with an inventor of a common cold and flu medicine. Now you have to ask yourself this question. Did MILV secure a remedy that pharmaceutical giants like Pfizer (PFE:NYSE) and Merck (MRK:NYSE) couldn’t ? Well that remains to be seen, but cold and flu remedies surely put MILV on the map as a quality trading vehicle, and event driven news on the matter could attract the eyeballs of super speculative penny stock traders to the name.
MILV For Agressive Investors
On the fundamental side, according to the most recent filing, MILV only does a little bit more than 10k in revenues. Plus, they only have 4.59k in cash. If you add in the fact that they have about 394k in debt, these numbers make MILV a true spec play, basically only suited for the most aggressive investors.
On the technical side, MILV has a bullish pattern, and is trading above its 50 and 200 DMA’s og 0.003 and 0.002 respectively. There is some support at 0.07 , but resistance looms at the psyche level of .10 cents.
Regardless of your bias, MILV remains a company that needs to be added permanently to penny stock lists.
Remember, penny stocks are news and event driven, and despite a lack of revenues of profits, Mistral Ventures could become a go to trading play if a flu epidemic breaks out. So forget the hype of FDA approvals for now, but still watch MILV.
More Penny Stock News, IPO Updates and Stock Market Research.